Sign in

Trial result ·

Biomarker Modulation by Aspirin and Metformin for Colorectal Cancer Prevention: Results from the ASAMET Randomized Phase II Trial.

Written based on 1 research study on PubMed, searched on 3 Nov 2026.

What was studied

This randomized trial tested aspirin and metformin in people with resected colorectal cancer. People got placebo, aspirin 100 mg daily, metformin 850 mg or both. This ran for 12 months. 51 people took part. Biopsies of normal colon lining and blood were taken at the start. They were taken again at 12 months. The main goal was NF-κB, a tissue marker.

What they found

Metformin cut global NF-κB versus placebo. Aspirin alone had no effect. The combination showed a cut that was not significant. Ki67 was unchanged overall. But the combination raised right-sided Ki67. No treatment changed pS6K. Toxicity was manageable. No serious adverse events occurred.

What it means for patients

The team says metformin cut NF-κB in normal colon lining. They say it may be a low-toxicity way to prevent cancer. They say aspirin did not help the markers. They say metformin merits further tests.

Why it is not certain yet

The trial measured tissue markers. It did not measure if cancer came back. 51 people were split across groups. The combination raised one marker in the right colon.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Biomarker Modulation by Aspirin and Metformin for Colorectal Cancer Prevention: Results from the ASAMET Randomized Phase II Trial.

PubMed · PMID 42895896

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Colorectal cancer publications